Advertisement
Screener

Jazz Pharmaceuticals plc (JAZZ) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Jazz Pharmaceuticals plc Financing Cash Flow

Jazz Pharmaceuticals plc (JAZZ) reported Financing Cash Flow of -$1.07 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03

  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$994.50M.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$78.50M.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $75.44M.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$10.92M, a 104.43% decline year-over-year.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for fiscal 2025 was -$873.38M, a 4357.07% decline from fiscal 2024.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for fiscal 2024 was $20.52M.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for fiscal 2023 was -$305.25M.
  • Jazz Pharmaceuticals plc net cash provided by (used in) financing activities for fiscal 2022 was -$529.49M, a 113.34% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30-$994.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
-$1.07B
10-Q · filed 2026-08-03
-$997.56M
derived: sum of 3 quarters · filed 2026-08-03
-$1.01B
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31-$78.50M
10-Q · filed 2026-05-05
-$3.06M
derived: sum of 2 quarters · filed 2026-05-05
-$13.98M
derived: sum of 3 quarters · filed 2026-05-05
-$138.38M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31$75.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$64.52M
derived: sum of 2 quarters · filed 2026-02-24
-$59.88M
derived: sum of 3 quarters · filed 2026-08-03
-$873.38M
10-K · filed 2026-02-24
2025-09-30-$10.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$135.32M
derived: sum of 2 quarters · filed 2026-08-03
-$948.82M
10-Q · filed 2025-11-05
-$957.10M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30-$124.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
-$937.90M
10-Q · filed 2026-08-03
-$937.99M
10-Q · filed 2025-08-06
-$946.17M
derived: sum of 3 quarters · filed 2026-08-03
-$699.75M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31-$813.50M
10-Q · filed 2026-05-05
-$813.47M
10-Q · filed 2025-05-07
-$821.77M
derived: sum of 2 quarters · filed 2026-05-05
-$575.35M
derived: sum of 3 quarters · filed 2026-05-05
-$736.43M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$8.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$238.15M
derived: sum of 2 quarters · filed 2026-02-24
$77.07M
derived: sum of 3 quarters · filed 2026-02-24
$20.52M
10-K · filed 2026-02-24
2024-09-30$246.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$85.34M
derived: sum of 2 quarters · filed 2025-11-05
$28.79M
10-Q · filed 2025-11-05
-$71.52M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$161.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$217.64M
10-Q · filed 2025-08-06
-$317.94M
derived: sum of 3 quarters · filed 2026-02-24
-$396.44M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31-$56.55M
10-Q · filed 2025-05-07
-$156.86M
derived: sum of 2 quarters · filed 2026-02-24
-$235.35M
derived: sum of 3 quarters · filed 2026-02-24
-$332.02M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$100.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$178.80M
derived: sum of 2 quarters · filed 2026-02-24
-$275.47M
derived: sum of 3 quarters · filed 2026-02-24
-$305.25M
10-K · filed 2026-02-24
2023-09-30-$78.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$175.16M
derived: sum of 2 quarters · filed 2024-11-07
-$204.95M
10-Q · filed 2024-11-07
-$185.35M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30-$96.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$126.45M
10-Q · filed 2024-08-01
-$106.86M
derived: sum of 3 quarters · filed 2025-02-26
-$395.91M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31-$29.79M
10-Q · filed 2024-05-02
-$10.19M
derived: sum of 2 quarters · filed 2025-02-26
-$299.25M
derived: sum of 3 quarters · filed 2025-02-26
-$288.47M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$19.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
-$269.46M
derived: sum of 2 quarters · filed 2025-02-26
-$258.68M
derived: sum of 3 quarters · filed 2025-02-26
-$529.49M
10-K · filed 2025-02-26
2022-09-30-$289.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$278.28M
derived: sum of 2 quarters · filed 2023-11-08
-$549.09M
10-Q · filed 2023-11-08
-$795.70M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$10.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$260.03M
10-Q · filed 2023-08-09
-$506.64M
derived: sum of 3 quarters · filed 2024-02-28
-$971.82M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31-$270.81M
10-Q · filed 2023-05-10
-$517.42M
derived: sum of 2 quarters · filed 2024-02-28
-$982.60M
derived: sum of 3 quarters · filed 2024-02-28
$3.68B
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$246.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$711.79M
derived: sum of 2 quarters · filed 2024-02-28
$3.95B
derived: sum of 3 quarters · filed 2024-02-28
$3.97B
10-K · filed 2024-02-28
2021-09-30-$465.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$4.20B
derived: sum of 2 quarters · filed 2022-11-09
$4.22B
10-Q · filed 2022-11-09
$4.27B
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$4.66B
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$4.68B
10-Q · filed 2022-08-03
$4.74B
derived: sum of 3 quarters · filed 2023-03-01
$4.72B
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$18.28M
10-Q · filed 2022-05-04
$74.15M
derived: sum of 2 quarters · filed 2023-03-01
$51.50M
derived: sum of 3 quarters · filed 2023-03-01
$694.03M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$55.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$33.22M
derived: sum of 2 quarters · filed 2023-03-01
$675.76M
derived: sum of 3 quarters · filed 2023-03-01
$528.07M
10-K · filed 2023-03-01
2020-09-30-$22.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$619.88M
derived: sum of 2 quarters · filed 2021-11-09
$472.19M
10-Q · filed 2021-11-09
$384.42M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$642.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
$494.85M
10-Q · filed 2021-08-03
$407.07M
derived: sum of 3 quarters · filed 2022-03-01
$387.61M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$147.68M
10-Q · filed 2021-05-04
-$235.46M
derived: sum of 2 quarters · filed 2022-03-01
-$254.93M
derived: sum of 3 quarters · filed 2022-03-01
-$311.08M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$87.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$107.24M
derived: sum of 2 quarters · filed 2022-03-01
-$163.40M
derived: sum of 3 quarters · filed 2022-03-01
-$293.75M
10-K · filed 2022-03-01
2019-09-30-$19.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
-$75.62M
derived: sum of 2 quarters · filed 2020-11-02
-$205.97M
10-Q · filed 2020-11-02
-$652.42M
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30-$56.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$186.50M
10-Q · filed 2020-08-04
-$632.96M
derived: sum of 3 quarters · filed 2021-02-23
-$646.93M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31-$130.35M
10-Q · filed 2020-05-05
-$576.80M
derived: sum of 2 quarters · filed 2021-02-23
-$590.78M
derived: sum of 3 quarters · filed 2021-02-23
-$561.90M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31-$446.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
-$460.43M
derived: sum of 2 quarters · filed 2021-02-23
-$431.56M
derived: sum of 3 quarters · filed 2021-02-23
-$479.13M
10-K · filed 2021-02-23
2018-09-30-$13.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$14.90M
derived: sum of 2 quarters · filed 2019-11-05
-$32.67M
10-Q · filed 2019-11-05
-$72.66M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$28.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
-$18.70M
10-Q · filed 2019-08-06
-$58.69M
derived: sum of 3 quarters · filed 2020-02-25
-$31.66M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31-$47.58M
10-Q · filed 2019-05-07
-$87.56M
derived: sum of 2 quarters · filed 2020-02-25
-$60.53M
derived: sum of 3 quarters · filed 2020-02-25
-$275.01M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31-$39.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
-$12.96M
derived: sum of 2 quarters · filed 2020-02-25
-$227.44M
derived: sum of 3 quarters · filed 2020-02-25
-$409.11M
10-K · filed 2020-02-25
2017-09-30$27.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
-$187.45M
derived: sum of 2 quarters · filed 2018-11-06
-$369.13M
10-Q · filed 2018-11-06
-$541.17M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30-$214.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$396.15M
10-Q · filed 2018-08-07
-$568.20M
derived: sum of 3 quarters · filed 2019-02-26
$327.02M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31-$181.67M
10-Q · filed 2018-05-08
-$353.72M
derived: sum of 2 quarters · filed 2019-02-26
$541.51M
derived: sum of 3 quarters · filed 2019-02-26
$511.77M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31-$172.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$723.18M
derived: sum of 2 quarters · filed 2019-02-26
$693.45M
derived: sum of 3 quarters · filed 2019-02-26
$540.99M
10-K · filed 2019-02-26
2016-09-30$895.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$865.49M
derived: sum of 2 quarters · filed 2017-11-07
$713.03M
10-Q · filed 2017-11-07
$589.17M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30-$29.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
-$182.19M
10-Q · filed 2017-08-08
-$178.69M
10-Q · filed 2016-08-09
-$306.05M
derived: sum of 3 quarters · filed 2018-02-27
-$400.48M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31-$152.46M
10-Q · filed 2017-05-09
-$144.52M
10-Q · filed 2016-05-10
-$276.32M
derived: sum of 2 quarters · filed 2018-02-27
-$370.74M
derived: sum of 3 quarters · filed 2018-02-27
-$363.52M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$123.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$218.28M
derived: sum of 2 quarters · filed 2018-02-27
-$211.06M
derived: sum of 3 quarters · filed 2018-02-27
-$214.32M
10-K · filed 2018-02-27
2015-09-30-$94.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08
-$87.20M
derived: sum of 2 quarters · filed 2016-11-08
-$90.46M
10-Q · filed 2016-11-08
-$100.90M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$7.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
$3.96M
10-Q · filed 2016-08-09
-$6.48M
derived: sum of 3 quarters · filed 2017-02-28
$256.79M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$3.26M
10-Q · filed 2016-05-10
-$13.70M
derived: sum of 2 quarters · filed 2017-02-28
$249.57M
derived: sum of 3 quarters · filed 2017-02-28
$210.11M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31-$10.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$252.83M
derived: sum of 2 quarters · filed 2017-02-28
$213.37M
derived: sum of 3 quarters · filed 2017-02-28
$711.03M
10-K · filed 2017-02-28
$712.88M
10-K · filed 2015-02-24
2014-09-30$263.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$223.81M
derived: sum of 2 quarters · filed 2015-11-09
$721.47M
10-Q · filed 2015-11-09
$692.75M
derived: sum of 4 quarters · filed 2016-02-23
2014-06-30-$39.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$458.21M
10-Q · filed 2015-08-05
$429.48M
derived: sum of 3 quarters · filed 2016-02-23
$383.76M
derived: sum of 4 quarters · filed 2016-02-23
2014-03-31$497.66M
10-Q · filed 2015-05-07
$468.94M
derived: sum of 2 quarters · filed 2016-02-23
$423.22M
derived: sum of 3 quarters · filed 2016-02-23
$470.67M
derived: sum of 4 quarters · filed 2016-02-23
2013-12-31-$28.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23
-$74.44M
derived: sum of 2 quarters · filed 2016-02-23
-$26.99M
derived: sum of 3 quarters · filed 2016-02-23
-$23.86M
10-K · filed 2016-02-23
-$24.03M
10-K · filed 2014-02-25
2013-09-30-$45.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
$1.73M
derived: sum of 2 quarters · filed 2014-11-04
$4.87M
10-Q · filed 2014-11-04
$8.46M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30$47.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05
$50.59M
10-Q · filed 2014-08-05
$54.18M
derived: sum of 3 quarters · filed 2015-02-24
$48.69M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31$3.13M
10-Q · filed 2014-05-08
$6.72M
derived: sum of 2 quarters · filed 2015-02-24
$1.24M
derived: sum of 3 quarters · filed 2015-02-24
$469.89M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31$3.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
-$1.90M
derived: sum of 2 quarters · filed 2015-02-24
$466.75M
derived: sum of 3 quarters · filed 2015-02-24
$448.53M
10-K · filed 2015-02-24
2012-09-30-$5.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05
$463.17M
derived: sum of 2 quarters · filed 2013-11-05
$444.94M
10-Q · filed 2013-11-05
$447.74M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$468.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
$450.43M
10-Q · filed 2013-08-06
$453.23M
derived: sum of 3 quarters · filed 2014-02-25
$419.62M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31-$18.23M
10-Q · filed 2013-05-07
-$15.42M
derived: sum of 2 quarters · filed 2014-02-25
-$49.04M
derived: sum of 3 quarters · filed 2014-02-25
-$48.32M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$2.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
-$30.81M
derived: sum of 2 quarters · filed 2014-02-25
-$30.09M
derived: sum of 3 quarters · filed 2014-02-25
-$33.08M
10-K · filed 2014-02-25
2011-09-30-$33.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
-$32.89M
derived: sum of 2 quarters · filed 2012-11-09
-$35.88M
10-Q · filed 2012-11-09
-$35.62M
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30$719.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07
-$2.27M
10-Q · filed 2012-08-07
-$2.01M
derived: sum of 3 quarters · filed 2013-02-26
-$6.41M
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31-$2.99M
10-Q · filed 2012-05-08
-$2.73M
derived: sum of 2 quarters · filed 2013-02-26
-$7.13M
derived: sum of 3 quarters · filed 2013-02-26
2010-12-31$263.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$4.14M
derived: sum of 2 quarters · filed 2013-02-26
-$27.53M
10-K · filed 2013-02-26
2010-09-30-$4.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08
-$27.79M
10-Q · filed 2011-11-08
2010-06-30-$23.39M
10-Q · filed 2011-08-03
2009-12-31$12.69M
10-K · filed 2012-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Viatris Inc (VTRS)United States$20.008B-0.00
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28